Core Viewpoint - QianYuan Pharmaceutical (300254) announced that its subsidiary, Jiangsu Jiayi Pharmaceutical Co., Ltd., received the approval notice for the listing application of Ebastine raw materials from the National Medical Products Administration [1] Group 1: Product Approval - Ebastine is indicated for the symptomatic treatment of allergic rhinitis with or without allergic conjunctivitis and chronic idiopathic urticaria [1] - The original manufacturer of Ebastine is INDUSTRIAS FARMACEUTICAS ALMIRALL, S.A. [1] Group 2: Market Impact - The Ebastine tablets produced by the subsidiary Hangzhou QianYuan BaoLing Pharmaceutical Co., Ltd. have passed the consistency evaluation [1] - Ebastine has been included in the Class B National Medical Insurance Directory, which may enhance its market accessibility [1] Group 3: Cost and Competitiveness - The approval of Ebastine raw materials for market entry is expected to further reduce the production costs of the formulation products [1] - This reduction in costs is anticipated to enhance the market competitiveness of the products [1]